Fisetin: a senolytic candidate, dosed in pulses, on mouse evidence

The senolytic idea is genuinely interesting and the pulse-dosing logic follows from it properly. What has not happened yet is a human trial reporting an outcome, and the amounts people take are extrapolated from animals by body weight.

Why pulses rather than daily

Animal-only or theoretical Senescent cells are cells that have stopped dividing but refuse to die, and they accumulate with age while secreting a mix of inflammatory signals known as the senescence-associated secretory phenotype. The senolytic hypothesis is that periodically killing them off produces a durable benefit, because the cells take months to accumulate again. If that is right, the drug does not need to be present continuously — it needs to be present in enough concentration, briefly, to trigger apoptosis in cells that have made themselves resistant to it.

That is the logic behind two or three days of high dose every few months rather than a daily supplement, and it is a coherent piece of reasoning rather than a marketing schedule. It is also completely different from how fisetin is sold as an everyday antioxidant flavonoid, and the two uses should not be conflated.

Established clinical use Fisetin itself is a flavonoid found in strawberries and other produce, with a long history as an ordinary dietary constituent. Its safety at food-level intake is not in question. The senolytic amounts are orders of magnitude above that.

The evidence, and the arithmetic behind the dose

Animal-only or theoretical The central finding is that fisetin reduced senescent cell burden across tissues and extended median and maximum lifespan in aged mice, alongside cell work showing selective killing of senescent cells. That is a real, notable result. What does not exist is a published human trial reporting a clinical outcome — trials have been registered and run, and results establishing benefit in people have not landed.

The dose arithmetic deserves scrutiny because it is where most of the confidence comes from. The commonly cited amounts derive from the mouse studies at around 20 mg/kg, scaled to a human by body weight. Straight body-weight scaling across species is not how dose translation is normally done, and fisetin’s oral bioavailability is poor and highly variable with the fat content of the meal. So the number in circulation is an estimate built on an approximation, and the app’s own drawbacks list says the human optimal dose is not established.

Monitoring reflects the state of things honestly: the app records inflammatory markers before and after a pulse, which is a plausible proxy and not a validated one. There is no test that tells you whether senescent cells were cleared.

Practical points

Absorption depends on being taken with fat, which is why the app’s row specifies a fatty meal. Content varies between products, as it does with any supplement, and this site names no brand and no testing service.

Off-label or community practice The interaction question is real: flavonoids at these concentrations affect drug-metabolising enzymes, and a two-day pulse at a gram or more per day is not the same exposure as eating strawberries. Anyone on prescription medication should treat the pulse as a medication event rather than a supplement, and anyone on an anticoagulant should be raising it with a clinician specifically.

The comparison worth knowing is with dasatinib, the prescription drug used in the same senolytic role, which does have human trial data and real risks. Fisetin is the option people can buy; that is a statement about availability, not about evidence. Anything on the drawbacks list below belongs with the clinician who knows your history.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Fisetin, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry. The third item — human optimal dose not established — is the one that undercuts the confident numbers everywhere else on the internet.

• High doses needed for senolytic effect (20mg/kg in studies)
• Pulse dosing protocol requires planning
• Human optimal dose not firmly established
• Quality varies significantly between supplements
• May cause temporary fatigue during senolytic pulse
• Long-term pulse protocol effects still being studied

Questions people actually ask

Has fisetin been shown to work in people?

No trial has reported a clinical outcome establishing benefit. The evidence is mouse lifespan and senescent cell clearance plus cell work. That is a real finding about mice.

Where does the 20 mg/kg dose come from?

From the mouse studies, scaled to human body weight directly. Straight body-weight scaling is not standard dose translation between species, and fisetin’s absorption is poor and variable — so the figure is an estimate on top of an approximation.

Why take it with fat?

Oral absorption is poor and improves substantially with dietary fat. The app’s own row specifies a fatty meal for that reason.

Is it the same as taking quercetin?

Both are flavonoids proposed as senolytics and they are frequently taken together, but they are different molecules with different potencies in the cell work. Quercetin is the one paired with dasatinib in the trial protocols.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.